sb-399885 hydrochloride

SB-399885 hydrochloride is an antagonist of 5-HT6 receptor.

SB399885 (SB 399885) is an effective, brain penetrant, and orally active antagonist of SR-6. It shows 200-fold selectivity for SR-6 over other serotonin receptors (pKi: 9.11, 8.81, and 9.02 for human recombinant, native rat, and native human SR-6 receptors, respectively).

SB-269970 hydrochloride (SB-269970A) , a hydrochloride salt form of SB-269970, is a 5-HT7 receptor antagonist (pKi of 8.3) and exhibits >50-fold selectivity against other receptors.

SB-224289 hydrochloride (SB-224289A) is a selective antagonist of 5-HT1B receptor, with anxiolytic effect.

SB-277011 hydrochloride (SB-277011A hydrochloride) is a potent, selective, orally active, dopamine D3 receptor (D3R) antagonist that crosses the blood-brain barrier with Ki values of 10.7 nM and 11.2 nM for rodent and human D3R, respectively. 277011 hydrochloride is 80-100 times more selective for D3 receptors than other dopamine receptors, acting on D3 receptors (pKi:8.0), D2 receptors (pKi:6.0), 5-HT1B receptors (pKi<5.2) and 5-HT1D receptors (pKi:5.9).

SB 216641 hydrochloride (SB-216641A) is a selective 5-HT1B/D receptor antagonist with anxiolytic properties that antagonizes the vasoconstrictor response mediated by sumatriptan. 10-O-Methylprotosapphosporin is an HbF inducer that can be used in the study of metabolic disorders and diabetes.

SB 204070 hydrochloride is an inhibitor of beta-lactamase, it is isolated from Spondias mombin.

5-HT2B/5-HT2C receptor antagonist

SB-435495 hydrochloride is a potent, selective, reversible, non-covalent, and orally active inhibitor of Lp-PLA2, exhibiting an IC50 of 0.06 nM [1] [3].

SB-743921 hydrochloride (SB743921 HCl) is an effective inhibitor of kinesin spindle protein, KSP, (Ki =0.1 nM).

SB 258585 hydrochloride is a 5-HT6 receptor antagonist.

SB-505124 hydrochloride functions as a selective, concentration-dependent inhibitor targeting TGF-β Receptor type I (ALK4, ALK5, ALK7), exhibiting IC50 values of 129 nM for ALK4 and 47 nM for ALK5. Notably, it does not affect ALK1, 2, 3, or 6.

Adezmapimod (SB 203580) hydrochloride is a selective ATP-competitive inhibitor of p38 MAPK, displaying IC50 values of 50 nM for SAPK2a/p38 and 500 nM for SAPK2b/p38β2. This compound also inhibits LCK, GSK3β, and PKBα, albeit with IC50 values 100-500 times higher than those for SAPK2a/p38. Additionally, Adezmapimod hydrochloride acts as an activator of autophagy and mitophagy [1].

SB-408124 Hydrochloride is a non-peptide OX1 receptor antagonist(Ki of 57 nM and 27 nM in both whole cell and membrane, respectively).

SB-612111 hydrochloride is a potent, novel orphan receptor for opioid receptors (ORL-1) antagonist with high affinity for hORL-1 and a Ki value of 0.33 nM. SB-612111 hydrochloride is able to act on mu-receptor (Ki: 57.6 nM), κ SB-612111 hydrochloride effectively antagonized the nociceptive effects of Nociceptin in an acute pain model.

SB 202190 hydrochloride is a selective and cell-permeable p38 MAPK inhibitor that inhibits p38α and p38β2 (IC50=50/100 nM). SB 202190 hydrochloride has anti-tumor activity and can also induce the differentiation of human embryonic stem cells into cardiomyocytes.

SB 258741 hydrochloride is a potent antagonist of the 5-HT 7 receptor, designed specifically for studying schizophrenia [1].

SB 203186 hydrochloride is a potent 5-HT4 receptor antagonist

SB 271046 hydrochloride (SB 271046A) is selective, orally active 5-HT6 antagonist (pKi values are 9.02-8.92, 6.35, 6.55, 6.27 at 5-HT6, 5-HT1A, 5-HT1D and D3, and 6.05, 5.95, 5.76, 5.73, 5.62, 5.55, 5.41, 5.39, 5.27 and < 4.99 at 5-HT1B, 5-HT1F, α1B, 5-HT2C, 5-HT2A, D2, 5-HT2B, 5-HT7, 5-HT4 and 5-HT1E respectively) and is > 200-fold selective over 55 other receptors, enzymes and ion channels. It increases extracellular aspartate and glutamate in the frontal cortex and exhibits anticonvulsant activity (EC50: 0.16 μM).

Selective 5-HT7 receptor antagonist

NOP receptor antagonist

SB 243213 hydrochloride is an orally active, selective and high-affinity antagonist of 5-hydroxytryptamine (5-HT)2C receptor(pKi of 9.37 and a pKb of 9.8).It has improved anxiolytic profile and has the potential for schizophrenia and motor disorders.